Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy

Wenze Sun, Tao Wang, Fan Shi, Jiquan Wang, Juan Wang, Beina Hui, Yingbing Zhang, Jinli Lu, Hongwei Chen, Zi Liu, Wenze Sun, Tao Wang, Fan Shi, Jiquan Wang, Juan Wang, Beina Hui, Yingbing Zhang, Jinli Lu, Hongwei Chen, Zi Liu

Abstract

Background: In cervical cancer patients with intermediate-risk factors, the optimal adjuvant therapy is still controversial. We undertook a randomized trial (ClinicalTrials.gov Identifier: NCT01418859) to compare the efficacy and toxicity of concurrent chemoradiotherapy with topotecan and cisplatin with radiotherapy alone in intermediate-risk cervical cancer patients.

Methods: Eligible patients were randomly assigned to one of three treatment arms including arm A (radiotherapy only,RT), arm B(concurrent chemoradiotherapy only, CCRT), and arm C (concurrent chemoradiotherapy with following consolidation chemotherapy, CCRT + CT). All eligible patients completed external RT (IMRT or 3D-CRT), receiving 45-50 Gy /25 f uniformly to the pelvis. Concurrent chemotherapy regimen was topotecan 0.75 mg/m(2) for days 1, 2 and 3, followed by cisplatin 25 mg/m(2) for days 1, 2 and 3. Three cycles of consolidation chemotherapy regimen was topotecan 1.5 mg/m(2) for days 1 and 2, and 0.75 mg/m(2) for day 3; followed by cisplatin 25 mg/m(2) for days 1, 2 and 3, repeated every 21 days. Adverse events of each group were investigated and compared.

Results: Thirty-nine patients enrolled onto the remaining regimens: 14 to RT, 15 to CCRT and 10 to CCRT + CT. Six patients (15.4%) did not complete the protocol treatment. Hematologic toxicity was more frequent and more severe in the CCRT and CCRT + CT arms compared with the RT arm. The incidence of grade 3-4 neutropenia was significantly different statistically between the RT, CCRT and CCRT + RT groups (15.4%, 46.7% and 100%, respectively; P = 0.002). Specially, three patients in CCRT + CT arm of all six patients who did not complete the protocol treatment discontinued planned therapy because of persistent grade 4 neutropenia. However, there were no significant differences in grade 3-4 non-hematologic toxicities between the three groups(all P > 0.05). Recurrence-free survival and overall survival of each group were not analyzed on account of a median follow-up of only 16 months.

Conclusions: Concurrent chemoradiotherapy with topotecan and cisplatin showed severe hematologic toxicity in intermediate-risk cervical cancer patients after radical hysterectomy. Thus, the study was closed ahead of schedule.

Trial registration: ClinicalTrials.gov Identifier: NCT01418859 .

References

    1. Bidus MA, Elcas JC. Cervical and vaginal cancer. In: Berek JS, editor. Novak EBerek & Novak’s gynecology. 14. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1403–56.
    1. Hacker NF, Friedlander ML, Berek JS. Hacker NFBerek & Hacker’s gynecologic oncology. 5. Philadelphia: Lippincott Williams & Wilkins; 2010. Cervical cancer; pp. 341–95.
    1. Peters WA, 3rd, Liu PY, Barrett RJ, 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.
    1. Delgado G, Bundy BN, Fowler WC, Jr, Stehman FB, Sevin B, Creasman WT, et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989;35:314–20. doi: 10.1016/0090-8258(89)90070-X.
    1. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:352–7. doi: 10.1016/0090-8258(90)90072-S.
    1. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–53. doi: 10.1056/NEJM199904153401502.
    1. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43. doi: 10.1056/NEJM199904153401501.
    1. Ryu HS. Concurrent chemoradiotherapy in cervical cancer (a new paradigm in cervical cancer treatment) Yonsei Med J. 2002;43:749–53. doi: 10.3349/ymj.2002.43.6.749.
    1. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol. 1999;73:177–83. doi: 10.1006/gyno.1999.5387.
    1. Ho CM, Chien TY, Huang SH, Wu CJ, Shih BY, Chang SC. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecol Oncol. 2004;93:458–64. doi: 10.1016/j.ygyno.2004.01.026.
    1. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169–76. doi: 10.1016/j.ijrobp.2005.10.019.
    1. Tuipae S, Yanaranop M, Oniem N. Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors. J Med Assoc Thai. 2012;95(Suppl 3):S117–24.
    1. Muderspach LI, Blessing JA, Levenback C, Moore JL., Jr A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81:213–5. doi: 10.1006/gyno.2000.6024.
    1. Long HJ, 3rd, Bundy BN, Grendys EC, Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626–33. doi: 10.1200/JCO.2005.10.021.
    1. Whitney CW, Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. January 2005. Available at: . Accessed July 1, 2005.
    1. Soisson AP, Soper JT, Clarke-Pearson DL, Berchuck A, Montana G, Creasman WT. Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol. 1990;37:390–5. doi: 10.1016/0090-8258(90)90374-T.
    1. Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS. Comparison of chemoradiation with radiation as postoperative adjuvant therapy in cervical cancer patients with intermediate-risk factors. Eur J Surg Oncol. 2009;35:192–6. doi: 10.1016/j.ejso.2008.04.004.
    1. Ryu SY, Park SI, Nam BH, Cho CK, Kim K, Kim BJ, et al. Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors? Int J Radiat Oncol Biol Phys. 2011;79:794–9. doi: 10.1016/j.ijrobp.2009.11.019.
    1. Lee TY, Jeung YJ, Lee CJ, Kim HY, Kim SH, Kim WG. Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer. Obstet Gynecol Sci. 2013;56:15–21. doi: 10.5468/OGS.2013.56.1.15.
    1. Okazawa M, Mabuchi S, Isohashi F, Suzuki O, Yoshioka Y, Sasano T, et al. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer. 2013;23:567–75. doi: 10.1097/IGC.0b013e31828703fd.
    1. Cetina L, Rivera L, Hinojosa J, Poitevin A, Uribe J, López-Graniel C, et al. Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five year results. BMC Womens Health. 2006;6:3. doi: 10.1186/1472-6874-6-3.
    1. Lee TS, Kang SB, Kim YT, Park BJ, Kim YM, Lee JM, et al. Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 2013;86:304–10. doi: 10.1016/j.ijrobp.2013.01.035.
    1. Vrdoljak E, Prskalo T, Omrcen T, Situm K, Boraska T, Frleta Ilić N, et al. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study. Int J Radiat Oncol Biol Phys. 2005;61:824–9. doi: 10.1016/j.ijrobp.2004.06.248.
    1. Zhang MQ, Liu SP, Wang XE. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study. Int J Radiat Oncol Biol Phys. 2010;78:821–7. doi: 10.1016/j.ijrobp.2009.08.069.
    1. Choi CH, Lee YY, Kim MK, Kim TJ, Lee JW, Nam HR, et al. A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiation in cervical cancer. Int J Radiat Oncol Biol Phys. 2011;81:1252–7. doi: 10.1016/j.ijrobp.2010.07.2006.
    1. Kim HS, Kim MK, Kim HJ, Han SS, Kim JW. Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer. Cancer Res Treat. 2012;44:97–103. doi: 10.4143/crt.2012.44.2.97.
    1. Dische S. Radiotherapy of cervical cancer. Clin Obstet Gynaecol. 1985;12:203–27.
    1. Barter JF, Soong SJ, Shingleton HM, Hatch KD, Orr JW., Jr Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Gynecol Oncol. 1989;32:292–6. doi: 10.1016/0090-8258(89)90627-6.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe